WP3 will involve the validation of the (ZW800-1-cRGD-TCO) construct / integrin αvβ3 target combination across the subcellular, cellular, endoscopic and macroscopic levels using state-of-art technologies. The objective is to show the viability of pretargeting the probe against integrin αvβ3 in order to identify a minimum tumour margin distance during intraoperative image-guided surgery. The probe will be tested in vitro and in vivo to characterise its binding properties and its prevalence at the tumour-normal tissue interface. Expression profiles will also be determined in the different cell lines.
Overview of all packages...